Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$111,223 Mln
Revenue (TTM)
$35,484 Mln
Net Profit (TTM)
$4,613 Mln
ROE
0.1 %
ROCE
6.1 %
P/E Ratio
24.2
P/B Ratio
2.3
Industry P/E
44.78
EV/EBITDA
13.9
Div. Yield
3.3 %
Debt to Equity
0.6
Book Value
$38.2
EPS
$--
Face value
--
Shares outstanding
1,283,884,964
CFO
$62,337.00 Mln
EBITDA
$87,217.00 Mln
Net Profit
$38,845.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Medtronic PLC (MDT)
| -9.8 | -11.3 | -9.8 | -2.1 | 2.4 | -6.0 | 1.4 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P 100
| -7.2 | -4.1 | -6.5 | 18.0 | 19.6 | 12.0 | 13.3 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Medtronic PLC (MDT)
| 20.3 | -3.0 | 6.0 | -24.9 | -9.8 | 5.7 | 27.3 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Medtronic PLC (MDT)
|
86.6 | 111,223.0 | 35,484.0 | 4,614.0 | 17.7 | 9.5 | 24.2 | 2.3 |
| 115.5 | 32,662.3 | 7,065.0 | 1,290.0 | 21.8 | 19.4 | 25.5 | 4.7 | |
| 70.2 | 13,691.2 | 4,151.9 | 401.4 | 11.1 | 4.8 | 34.9 | 1.7 | |
| 2.3 | 7.2 | 0.0 | -8.5 | -89,802.3 | -292.9 | -- | 3.2 | |
| 174.0 | 28,599.2 | 3,195.3 | 908.9 | 21.0 | 13.9 | 31.9 | 3.9 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable... cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland. Read more
Chairman of the Board & CEO
Mr. Geoffrey Straub Martha
Chairman of the Board & CEO
Mr. Geoffrey Straub Martha
Headquarters
Galway
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Medtronic PLC (MDT) is $86.63 (NYSE) as of 02-Apr-2026 18:33 EDT. Medtronic PLC (MDT) has given a return of 2.43% in the last 3 years.
The P/E ratio of Medtronic PLC (MDT) is 24.20 times as on 02-Apr-2026, a 46 discount to its peers’ median range of 44.78 times.
The P/B ratio of Medtronic PLC (MDT) is 2.26 times as on 02-Apr-2026, a 23 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Medtronic PLC (MDT) are Rs 106.33 and Rs 79.55 as of 05-Apr-2026.
Medtronic PLC (MDT) has a market capitalisation of $ 111,223 Mln as on 02-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Medtronic PLC (MDT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.57
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.